基于神经元凋亡机制探究平痫冲剂及其拆方的抗痫作用机制

doi:10.20274/j.cnki.issn.2025.04.004

Abstract

Abstract:

Objective To observe the anti-epileptic effects of Pingxian granules and its split formula, and explore their anti-epileptic mechanisms. Methods Totally 270 4-week-old Wistar rats were randomly divided into a blank control group of 36 rats and a model group of 234 rats. The epilepsy model was prepared by intraperitoneal injection of pentylenetetrazole. After the successful preparation of epilepsy model rats（n=216）, they were randomly divided into a model control group, a positive control group, a phlegm-resolving group, a blood stasis-removing group, wind-stopping group, and a Pingxian group, with 36 rats in each group. The positive control group was given 0.36 g/kg of sodium valproate (VPA), while the phlegm-resolving group, blood stasis-removing group, and wind-stopping group were all given medications from the split formula of Pingxian granules. The phlegm-resolving group was given 1.40 g/kg of phlegm-resolving drugs (Acorus tatarinowii and Dannanxing) by gavage; the blood stasis-removing group was given 2.08 g/kg of phlegm-resolving drugs (Danshen and Yujin) by gavage; the wind-stopping group was given 2.96 g/kg of wind-stopping drugs (Bombyx mori, Tianma, Daizheshi and Baishao) by gavage; the Pingxian group was given 3.22 g/kg of anti-epileptic drugs (composed of the aforementioned phlegm-resolving drugs, blood stasis-removing drugs, and wind-stopping drugs) by gavage. The blank control group and model control group were given an equal amount of physiological saline by gavage. Each group was treated by gavage for 21 days. Results Compared with the model control group, the Pingxian group and each group with split formula showed reduced positive expression of Bax protein at 24 h, 48 h, 72 h, 7 d, 14 d, and 21 d after drug intervention(P<0.05). Compared with the model control group, the Pingxian group and each group with split formula showed enhanced positive expression of Bcl-2 protein at 48 h, 72 h, 7 d, 14 d, and 21 d after drug intervention(P<0.05). Compared with the model control group, the positive control group, phlegm-resolving group, blood stasis-removing group, wind-stopping group and Pingxian group showed varying degrees of repair in the number and morphology of pyramidal neurons, with the Pingxian group showing greater improvement than the other groups with split formula, while the blood stasis-removing group showed no significant changes. Conclusion Pingxian granules and its split formula may exert anti-epileptic effects by inhibiting neuronal apoptosis, downregulating Bax protein expression, and upregulating Bcl-2 protein expression.

Key words: Epilepsy, Neuronal apoptosis, Pingxian granules, Mechanism research, Child

CLC Number:

R742.1

Lü GAO, Chi LIU, Zhengyu YAO, Yijue JING, Liping WU, Zhenggang SHI. Exploring the anti-epileptic mechanism of Pingxian granules and its split formula based on neuronal apoptosis[J]. Chinese Pediatrics of Integrated Traditional and Western Medicine, 2025, 17(4): 292-297.

Figures/Tables 3

Table 1

Table 2

Table 3

References 18

[1]	Asadi-Pooya AA, Brigo F, Lattanzi S, et al. Adult epilepsy[J]. Lancet, 2023, 402(10399): 412-424.
[2]	Ding D, Zhou D, Sander JW, et al. Epilepsy in China: major progress in the past two decades[J]. Lancet Neurol, 2021, 20(4): 316-326.
[3]	Bertheloot D, Latz E, Franklin BS. Necroptosis, pyroptosis and apoptosis: an intricate game of cell death[J]. Cell Mol Immunol, 2021, 18(5): 1106-1121.
[4]	马喜凤, 张士卿. 平痫汤治疗小儿癫痫35例[J]. 中医杂志, 2013, 54(4): 336-338.
[5]	田茸, 张士卿, 史正刚, 等. 平痫汤治疗癫痫62例疗效观察[J]. 中国中医药信息杂志, 2009, 16(6): 69-70.
[6]	高旅, 刘驰, 吴丽萍, 等. 平痫冲剂对幼龄癫痫大鼠脑组织神经元ICAM-1、Cx43蛋白表达的影响研究[J]. 时珍国医国药, 2019, 30(5): 1060-1063.
[7]	高旅, 尚菁, 史正刚, 等. 平痫冲剂对幼龄癫痫模型大鼠血脑屏障通透性及相关蛋白Cx43、ICAM-1表达的影响[J]. 山西中医, 2021, 37(2): 53-56.
[8]	黄继汉, 黄晓晖, 陈志扬, 等. 药理试验中动物间和动物与人体间的等效剂量换算[J]. 中国临床药理学与治疗学, 2004, 9(9): 1069-1072.
[9]	朱慧, 成举森, 张满. 基于跨理论模型的行为训练在癫痫患儿康复中的临床应用[J]. 中国中西医结合儿科学, 2023, 15(6): 544-548.
[10]	Fricker M, Tolkovsky AM, Borutaite V, et al. Neuronal cell death[J]. Physiol Rev, 2018, 98(2): 813-880.
[11]	Bengzon J, Mohapel P, Ekdahl CT, et al. Neuronal apoptosis after brief and prolonged seizures[J]. Prog Brain Res, 2002, 135: 111-119.
[12]	Zhang K, Yang Z, Yang Z, et al. Targeting microglial GLP1R in epilepsy: a novel approach to modulate neuroinflammation and neuronal apoptosis[J]. Eur J Pharmacol, 2024, 981: 176903.
[13]	Knight T, Luedtke D, Edwards H, et al. A delicate balance - The BCL-2 family and its role in apoptosis, oncogenesis, and cancer therapeutics[J]. Biochem Pharmacol, 2019, 162: 250-261.
[14]	Kale J, Osterlund EJ, Andrews DW. BCL-2 family proteins: changing partners in the dance towards death[J]. Cell Death Differ, 2018, 25(1): 65-80.
[15]	Kirkland RA, Franklin JL. Bax, reactive oxygen, and cytochrome c release in neuronal apoptosis[J]. Antioxid Redox Signal, 2003, 5(5): 589-596.
[16]	Adams JM, Cory S. The BCL-2 arbiters of apoptosis and their growing role as cancer targets[J]. Cell Death Differ, 2018, 25(1): 27-36.
[17]	Jain S, LaFrancois JJ, Gerencer K, et al. Increasing adult-born neurons protects mice from epilepsy[J]. eLife, 2024, 12: RP90893.
[18]	曲珍珍, 王维平, 毛卓锋, 等. PTZ诱导孕鼠痫性发作对胎鼠海马中bax、bcl-2、capase-3表达的影响[J]. 中风与神经疾病杂志, 2012, 29(10): 883-885.

组别	n	24 h	48 h	72 h	7 d	14 d	21 d
模型对照组	6	6（100）	6（100）^*	6（100）	6（100）	6（100）^*	6（100）
阳性对照组	6	5（83）	2（33）	0（0）	0（0）	0（0）	0（0）
化痰组	6	6（100）	6（100）	6（100）	5（83）	3（50）	2（33）
祛瘀组	6	6（100）^*	6（100）	6（100）	6（100）	5（83）	5（83）
息风组	6	6（100）	6（100）	6（100）	4（67）	3（50）	2（33）
平痫组	6	6（100）	5（83）	4（67）	0（0）	0（0）	0（0）

组别	n	24 h	48 h	72 h	7 d	14 d	21 d	F值	P值
空白对照组	3	0.23±0.02	0.23±0.01	0.22±0.02	0.23±0.01	0.23±0.02	0.23±0.02	0.16	0.98
模型对照组	3	0.41±0.02^a	0.40±0.02^a	0.42±0.02^a	0.42±0.02^a	0.42±0.01^a	0.43±0.02^a	1.03	0.44
阳性对照组	3	0.35±0.02^b	0.33±0.02^b	0.31±0.01^bd	0.25±0.00^bd	0.22±0.02^bd	0.21±0.00^bd	48.23	<0.05
化痰组	3	0.38±0.01^b	0.36±0.03^b	0.35±0.03^b	0.32±0.00^bcd	0.28±0.01^bd	0.25±0.03^bcd	15.04	<0.05
祛瘀组	3	0.37±0.02^b	0.37±0.02	0.35±0.02^b	0.31±0.01^bcd	0.27±0.02^bd	0.26±0.01^bcd	19.59	<0.05
息风组	3	0.37±0.01^b	0.37±0.01	0.35±0.02^b	0.32±0.01^bcd	0.28±0.01^bd	0.26±0.02^bcd	32.85	<0.05
平痫组	3	0.36±0.01^b	0.35±0.02^b	0.34±0.01^b	0.28±0.02^bd	0.25±0.02^bd	0.22±0.01^bd	40.80	<0.05
F值		36.35	23.32	28.37	61.50	40.52	51.37
P值		<0.05	<0.05	<0.05	<0.05	<0.05	<0.05

组别	n	24 h	48 h	72 h	7 d	14 d	21 d	F值	P值
空白对照组	3	0.36±0.02	0.36±0.01	0.36±0.02	0.36±0.02	0.36±0.02	0.36±0.02	0.00	1.00
模型对照组	3	0.24±0.02^a	0.24±0.02^a	0.24±0.02^a	0.25±0.01^a	0.25±0.01^a	0.25±0.01^a	0.12	0.99
阳性对照组	3	0.28±0.02^b	0.28±0.02^b	0.30±0.02^b	0.33±0.02^bd	0.36±0.05^bd	0.36±0.02^bd	5.51	<0.05
化痰组	3	0.26±0.00	0.26±0.02	0.29±0.02^b	0.30±0.03^b	0.32±0.02^bd	0.34±0.01^bcd	8.42	<0.05
祛瘀组	3	0.26±0.02	0.27±0.01^b	0.29±0.02^b	0.31±0.02^bd	0.34±0.02^bd	0.34±0.01^bcd	11.70	<0.05
息风组	3	0.26±0.03	0.28±0.02^b	0.28±0.02^b	0.31±0.02^bd	0.32±0.02^bd	0.33±0.01^bcd	5.17	<0.05
平痫组	3	0.27±0.02	0.28±0.01^b	0.29±0.02^b	0.32±0.02^bd	0.32±0.02^bd	0.34±0.03^bd	3.90	<0.05
F值		11.49	14.86	11.00	7.37	6.45	14.79
P值		<0.05	<0.05	<0.05	<0.05	<0.05	<0.05

Exploring the anti-epileptic mechanism of Pingxian granules and its split formula based on neuronal apoptosis

RichHTML

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

Figures/Tables 3

References 18

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Mingqing LUO, Shuxin SUN, Jing LI. Clinical research advances in auricular acupoint therapy for pediatric tic disorders [J]. Chinese Pediatrics of Integrated Traditional and Western Medicine, 2025, 17(4): 277-280.
[2]	Qingmei ZHANG, Baiye XU, Haidao WANG, Zhen CHEN, Tingting CHEN. Investigation and analysis of sleep quality in children with tic disorders [J]. Chinese Pediatrics of Integrated Traditional and Western Medicine, 2025, 17(4): 287-291.
[3]	Ziying LI, Yuesheng WANG, Xiaoqin LI. Application of cyproheptadine in digestive disorders in children [J]. Chinese Pediatrics of Integrated Traditional and Western Medicine, 2025, 17(4): 298-301.
[4]	Xingqian YI, Jing Ying NG, Zhiyi XIONG, Xiaofan CHEN, Ying LIU, Xiaoyan LI, Li WANG. Analysis of intestinal microbiome characteristics of children with autism in China based on literature research [J]. Chinese Pediatrics of Integrated Traditional and Western Medicine, 2025, 17(4): 302-312.
[5]	Zengquan ZHONG, Xue JIANG, Shuangquan SUN, Yiming LI, Wei LI, Xin ZHANG, Hong LI, Zhihai LYU. Efficacy and follow-up of ultrasound-guided botulinum toxin type A injection for lower limb spasticity in cerebral palsy [J]. Chinese Pediatrics of Integrated Traditional and Western Medicine, 2025, 17(4): 313-319.
[6]	Li ZHANG, Yanfei YANG, Yanfen WANG. Clinical features and prognostic analysis of 21 cases of histiocytic necrotizing lymphadenitis in children [J]. Chinese Pediatrics of Integrated Traditional and Western Medicine, 2025, 17(4): 324-329.
[7]	Ye LI, Yuhuan WAN, Zhuo LI. Construction and validation of risk prediction model for postoperative malnutrition in children with intracranial space-occupying lesions [J]. Chinese Pediatrics of Integrated Traditional and Western Medicine, 2025, 17(4): 330-335.
[8]	Bowen XU, Bin XIE, Xuefeng WANG. Professor Wang Xuefeng's experience in treating attention-deficit hyperactivity disorder based on liver and kidney [J]. Chinese Pediatrics of Integrated Traditional and Western Medicine, 2025, 17(4): 336-339.
[9]	Guiwen LI, Shangan SI, Guiju ZHANG. Treatment for childhood obesity combined with precocious puberty based on entropy disease theory [J]. Chinese Pediatrics of Integrated Traditional and Western Medicine, 2025, 17(4): 340-345.
[10]	Yanli CUI, Li XU. Treatment for pediatric Henoch-Schönlein purpura based on the theory of "Xuanfu-Qixue-Luomai" [J]. Chinese Pediatrics of Integrated Traditional and Western Medicine, 2025, 17(4): 346-350.
[11]	Hangbo LIN, Liping SUN. An analysis of the experience in the treatment of pediatric chronic urticaria based on the theory of lung heat [J]. Chinese Pediatrics of Integrated Traditional and Western Medicine, 2025, 17(4): 351-354.
[12]	Yuechen SUN, Ru XU, Weiwei LIU, Yadong LI. Differential treatment by stages for mycoplasma pneumonia in children based on the theory of "Xuanfu-Qiye-Luomai" of the lung [J]. Chinese Pediatrics of Integrated Traditional and Western Medicine, 2025, 17(4): 355-358.
[13]	Weizhuo LIU, Liping SUN. Three-phase treatment for children with allergic rhinitis with wind-cold syndrome of the lung meridian based on the "Ying-Wei theory" combined with syndrome differentiation of viscera [J]. Chinese Pediatrics of Integrated Traditional and Western Medicine, 2025, 17(4): 359-362.
[14]	. Clinical practice guidelines for integrative Chinese and western medicine in children with enuresis (2025) [J]. Chinese Pediatrics of Integrated Traditional and Western Medicine, 2025, 17(3): 185-198.
[15]	Yuanjun LU, Na CHEN, Yang YANG, Man CHENG, Duojian LI, Qiuyue LI, Zhu CHEN. Differentiated treatment for central precocious puberty based on the five viscera and the theory of "Tiangui" [J]. Chinese Pediatrics of Integrated Traditional and Western Medicine, 2025, 17(3): 203-207.